drugset / Trial / NCT00073736
Safety and Tolerability of I.V. Infusion of MB07133 in Patients With Unresectable Hepatocellular Carcinoma
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Hepatocellular carcinoma (HCC) is the most common primary cancer of the liver. MB07133 is being developed for the treatment of inoperable HCC, using a platform technology known as HepDirectTM, which enables drugs to be targeted specifically to the liver. The objective for this study is to determine the safety and tolerability of MB07133.
Timeline
- Start
- 2003-09
- Primary completion
- 2007-07
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MB07133 | Small molecule | 300 mg/m2 | Intravenous |
| Subject | MB07133 | Small molecule | 600 mg/m2 | Intravenous |
| Subject | MB07133 | Small molecule | 1200 mg/m2 | Intravenous |
| Subject | MB07133 | Small molecule | 1800 mg/m2 | Intravenous |
| Subject | MB07133 | Small molecule | 2400 mg/m2 | Intravenous |